查看購物車
  • Japanese
  • Korean
非滲出性視網膜疾病治療市場（2026 年）
市場調查報告書
商品編碼
2122053

非滲出性視網膜疾病治療市場（2026 年）

2026 Nonexudative Retinal Disease Pharmaceuticals Market Report
出版日期: | 出版商: Market Scope, LLC | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

什麼是新的：

「非滲出性視網膜疾病治療市場（2026）」報告提供了針對補體抑制劑、基因和細胞療法以及其他新興非滲出性視網膜疾病療法的最新疾病估計和預測。該報告檢驗了補體抑制劑在美國的引入及其地理擴張趨勢，同時追蹤最新的企業資料和臨床階段藥物研發項目，包括目前正在接受監管部門批准的項目。此外，報告還涵蓋了前景廣闊的藥物遞送平台的最新研發進展。

概述：

「非滲出性視網膜疾病治療市場（2026）」報告全面分析了目前及新興的治療方案，涵蓋了地圖狀萎縮、老齡化黃斑部病變（AMD）及其他非滲出性視網膜疾病。報告檢視了關鍵市場趨勢、病患經濟狀況、健保報銷趨勢以及未來五年的成長檢驗，此外還涉及補體抑制劑、基因療法、緩釋技術、抗氧化劑和其他新興治療方法。

此外，該報告還包括詳細的銷售量和收入預測、按產品類型分類的市場佔有率估計值，以及 19 家主要競爭對手的概況（包括對每家公司的策略、產品線和未來展望的分析）。

價格：

本報告提供兩種許可類型：

  • 單一使用者許可證的價格為 5700 美元。
  • 企業版許可證定價為 8,550 美元（包含報告中所有表格和圖表的補充 Excel 文件以及報告摘要幻燈片）。

兩種授權均包含電子版PDF文件。印刷版需另加250美元。

單一用戶許可

  • 單一使用者許可證允許單一企業場所內的一名使用者存取此報告。
  • 報告的紙本副本無法複製（可另行購買紙本副本）。
  • 報告的 PDF 版本（如果購買）不能複製，並且只能儲存在一台電腦上（公司伺服器除外）。
  • 您僅可列印一份本出版物供公司內部使用。
  • 使用者可以將報告中的資訊用於簡報和內部報告，但必須包含對 Market Scope 的完整版權聲明。
  • 用戶不得與購買該報告的公司以外的任何人共用該報告（或其中包含的資訊）。

企業許可證

  • 購買企業授權後，您可以在採購組織內不受使用者數量限制地使用這些報告。
  • 根據全球授權合約，採購機構有權不時與第三方（投資者、顧問等）共用報告。但前提是，這些第三方已與採購機構簽訂保密協議，並同意受全球授權合約協議條款的約束。
  • 採購組織的員工可以將報告中的資訊用於簡報和內部報告，但前提是必須在「市場範圍」中包含完整的版權聲明。
  • 購買價格包含一份可列印的 PDF 報告文件（購買機構可以列印多份供內部使用）。
  • 購買價格包含一個補充 Excel 文件，其中包含所購買報告中的所有表格和圖表。
  • 付款方式可以是信用卡付款或發票付款。

目錄

「非滲出性視網膜疾病治療市場（2026 年）」以數據為依據，清楚展現了地圖狀萎縮、萎縮性老齡化黃斑部病變和其他非滲出性視網膜疾病的治療格局演變。

報告的主要內容如下：

  • 疾病概述與風險因素：本節討論非滲出性視網膜疾病、其病因、疾病進展及其與整體健康和生活方式的關係。
  • 診斷與治療現況：我們將探討診斷技術、病患管理趨勢以及藥物介入的日益重要的角色。
  • 全球視網膜醫療保健概況：概述全球視網膜醫療保健服務、患者就醫途徑、專家分佈和治療採用趨勢。
  • 目前市面上可用的治療方法：對已通過核准的藥品和生技藥品的分析（包括市場滲透率、定價趨勢和競爭地位）。
  • 開發平臺：對正在研發中的臨床實驗藥物進行審查，包括補體抑制劑、基因療法和緩釋製劑。這些藥物將塑造下一代醫學。
  • 公司簡介與臨床前活動：開發或銷售非滲出性視網膜疾病治療方法的公司簡介，以及其他進行臨床前計畫的公司名單。
簡介目錄

What's New:

The “2026 Nonexudative Retinal Disease Pharmaceuticals Market Report” features new disease estimates and forecasts for complement inhibitors, gene and cellular therapies, and other emerging approaches for treating nonexudative retinal diseases. It examines the US experience with complement inhibitors and their continued geographic expansion, while tracking updated companies and clinical-stage drug-development programs, including those being submitted for regulatory approval. The report also reflects the latest development stages of promising drug-delivery platforms.

Description:

The “2026 Nonexudative Retinal Disease Pharmaceuticals Market Report” provides a comprehensive analysis of current and emerging therapies for geographic atrophy, dry AMD, and other nonexudative retinal diseases. It examines complement inhibitors, gene therapies, sustained-release technologies, antioxidants, and other evolving treatment approaches, along with key market trends, patient economics, reimbursement dynamics, and five-year growth forecasts.

The report also features detailed unit and revenue projections, market share estimates by product category, and profiles of 19 leading competitors, including insights into their strategies, pipelines, and future outlooks.

Pricing:

2 licensing types are available for this report:

  • The price of the single-user license is $5,700.
  • The price of the enterprise license is $8,550 (includes supplemental Excel file with all the tables and figures in the report, and report summary slides).

Both licenses include an electronic PDF. Printed copies may be purchased for an additional $250.

SINGLE USER LICENSE

  • The Single User License allows for the use of a report by a single user within one corporate location.
  • The report paper copy may not be reproduced (additional paper copies available for purchase).
  • Report PDF copy can not be copied (if purchased) and must remain on one computer (not a company server).
  • Only a single copy of the publication may be printed for internal use.
  • Users may include information in the report in presentations and internal reports by providing full copyright credit to Market Scope.
  • Users may not share the report (or any information contained therein) with any other person or persons outside the corporate location for which the report is purchased.

ENTERPRISE LICENSE

  • The Enterprise License allows for the use of a report by unlimited users within the purchasing organization.
  • Purchasing organization shall have the right to share the report with third parties. (investors, consultants, etc.) from time to time under the global license agreement, provided that such third parties have a confidentiality agreement with the purchasing organization and agree to be bound by the terms of the global license agreement.
  • Employees of the purchasing organization can include information given in the report in presentations and internal reports by providing full copyright credit to Market Scope.
  • Purchase price includes a printable PDF file of the report (purchasing organization may print multiple copies for use within the organization).
  • Purchase price includes a supplemental Excel file containing all the tables and figures included in the purchased report.
  • Pay by credit card or by invoice.

Table of Contents

The “2026 Nonexudative Retinal Disease Pharmaceuticals Market Report” provides a clear, data-driven view of the evolving treatment landscape for geographic atrophy, dry AMD, and other nonexudative retinal diseases.

Coverage highlights include:

  • Disease overview and risk factors: discussion of nonexudative retinal diseases, their causes, disease progression, and links to systemic health and lifestyle.
  • Diagnosis and treatment landscape: examination of diagnostic technologies, patient management trends, and the growing role of pharmaceutical intervention.
  • Global retinal care environment: overview of global retinal care delivery, patient access, specialist distribution, and treatment adoption trends.
  • Current therapies in the market: analysis of approved pharmaceuticals and biologics, including market penetration, pricing dynamics, and competitive positioning.
  • Development pipeline: review of investigational agents in development—complement inhibitors, gene therapies, sustained-release devices, and more—shaping the next generation of care.
  • Company profiles and preclinical activity: profiles of companies developing or marketing therapies for nonexudative retinal disease, plus a listing of additional firms with preclinical programs.